OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But Vertex Pharmaceuticals could also compete with a drug candidate from a recent acquisition.
The post Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder appeared first on MedCity News.
Stopping GLP-1 drugs often brings weight back. A small trial suggests ways to slow it
In a randomized pilot trial of 39 adults, researchers found that participants receiving medically tailored meals or Noom regained about 3.6% of their body weight
